- Home
- SPRO vs IDN Comparison
SPRO vs IDN Comparison
Compare SPRO & IDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- IDN
- Stock Information
- Founded
- SPRO 2013
- IDN 1994
- Country
- SPRO United States
- IDN United States
- Employees
- SPRO N/A
- IDN N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- IDN Computer Software: Prepackaged Software
- Sector
- SPRO Health Care
- IDN Technology
- Exchange
- SPRO Nasdaq
- IDN Nasdaq
- Market Cap
- SPRO 40.5M
- IDN 46.8M
- IPO Year
- SPRO 2017
- IDN 1999
- Fundamental
- Price
- SPRO $0.62
- IDN $2.83
- Analyst Decision
- SPRO Buy
- IDN Buy
- Analyst Count
- SPRO 4
- IDN 2
- Target Price
- SPRO $5.00
- IDN $3.00
- AVG Volume (30 Days)
- SPRO 113.5K
- IDN 47.0K
- Earning Date
- SPRO 05-13-2025
- IDN 05-13-2025
- Dividend Yield
- SPRO N/A
- IDN N/A
- EPS Growth
- SPRO N/A
- IDN N/A
- EPS
- SPRO N/A
- IDN N/A
- Revenue
- SPRO $47,977,000.00
- IDN $19,997,000.00
- Revenue This Year
- SPRO N/A
- IDN $7.60
- Revenue Next Year
- SPRO N/A
- IDN $10.02
- P/E Ratio
- SPRO N/A
- IDN N/A
- Revenue Growth
- SPRO N/A
- IDN 5.77
- 52 Week Low
- SPRO $0.51
- IDN $1.92
- 52 Week High
- SPRO $1.72
- IDN $4.46
- Technical
- Relative Strength Index (RSI)
- SPRO 41.34
- IDN 61.62
- Support Level
- SPRO $0.64
- IDN $2.47
- Resistance Level
- SPRO $0.75
- IDN $2.87
- Average True Range (ATR)
- SPRO 0.05
- IDN 0.17
- MACD
- SPRO -0.01
- IDN 0.03
- Stochastic Oscillator
- SPRO 21.63
- IDN 92.86
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.